{"id":"NCT02911857","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes","officialTitle":"An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF))","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-03","primaryCompletion":"2017-01-27","completion":"2017-01-27","firstPosted":"2016-09-22","resultsPosted":"2018-08-20","lastUpdate":"2018-08-20"},"enrollment":4,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Periodic Fevers Syndrome"],"interventions":[{"type":"BIOLOGICAL","name":"Canakinumab (AIN457)","otherNames":[]}],"arms":[{"label":"Canakinumab (ACZ885)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offered the opportunity for participants who completed Epoch 4 of the preceding CACZ885N2301 (NCT02059291) study to continue to be treated with ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development of ACZ885 in Periodic Fever Syndromes was suspended.","primaryOutcome":{"measure":"Number of Participants With Non-serious Adverse Events, Serious Adverse Events and Deaths","timeFrame":"Participants were followed for the duration until approval, an expected average of 3 months.","effectByArm":[{"arm":"TRAPS","deltaMin":1,"sd":null},{"arm":"HIDS/MKD","deltaMin":1,"sd":null},{"arm":"cfFMF","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["NASOPHARYNGITIS"]}}